ACR 2015 SAN FRANCISCO
- Oral presentations and posters
- Social events and social media
- Mentor/Mentee meetings

EULAR COURSES

NEWS FROM COUNTRY LIAISONS
Dear young rheumatologists and researchers in rheumatology,

We are happy to present you a new issue of EMEUNews about the Do-Not-Miss Topics of this year’s ACR annual meeting.

The ACR congress is one of the largest scientific events in Rheumatology. As it is now approaching, we provide a selection of oral presentations and posters that we consider to be noteworthy. Albeit this is a limited way of looking at the numerous scientific releases at ACR 2015, it might provide an overview of hot topics in each field of Rheumatology.

This current Newsletter also contains details about other events organized during the Congress.

EMEUNET is now active in social media hubs such as Facebook and Twitter, while maintaining the traditional website and the important physical (and personal) presence at major Rheumatology scientific events.

If this is your first contact with EMEUNET, we invite you to explore more and join us. If you are already part of our community, we kindly remind you that sharing is caring. Spread the word about our activities and work, and help us reach more young rheumatologists and researchers.

We hope you enjoy reading this Newsletter. We always welcome feedback, comments, suggestions and contributions.

We wish you a prolific and successful ACR 2015! See you in San Francisco!

Russka Shumnalieva, João Madruga Dias, Joanna Zalewska and Alessia Alunno on behalf of the Newsletter Subgroup

More information about EMEUNET can be found in http://emeunet.eular.org

You can also reach us through the following email emeunet@eular.ch

www.facebook.com/EMEUNET

www.twitter.com/EMEUNET

DIRECTORY

ACR 2015: ORAL PRESENTATIONS & POSTERS
Basic Research I
Basic Research II
RA I
RA II
RA III
Psoriatic Arthritis
Axial Spondyloarthritis
SLE and APS
Other connective tissue diseases
Imaging
Metabolic and Crystal Arthropathies
Osteoarthritis & Osteoporosis
Pediatric Rheumatology

GET TOGETHER @ACR 2015

MENTOR MENTEE MEETINGS

EDUCATIONAL EVENTS

NEWS FROM THE COUNTRY LIAISONS
**BASIC RESEARCH I**

Genetics, cartilage/synovium, osteoimmunology, animal models

Ania Olewicz-Gawlik

---

**ORAL PRESENTATIONS**

**Monday 09.11.2015 16:30**

Session: Biology and pathology of bone and joint: bone remodeling (South Esplanade 300)

Chiu YG (USA)

2084. Dendritic-cell specific transmembrane protein (DC-STAMP) modulates bone resorption in inflammatory arthritis and fracture repair

**Monday 09.11.2015 16:45**

Session: Genetics, Genomics and Proteomics (West 2011)

Asquit M (USA)

2097. HLA B27 expression profoundly shapes the host-microbiota metabolome

**Monday 09.11.2015 17:30**

Biology and Pathology of bone and joint: bone remodeling (South Esplanade 300)

Krishnamurthy A (Sweden)

2088. Immature dendritic cells are potent OC precursors in RA and are targeted by RA-specific antibodies

**Tuesday 10.11.2015 14:30**

Session: Systemic sclerosis, fibrosing syndromes and Raynaud’s - pathogenesis, animal models and genetics II (South Esplanade 301)

Ramos PS (USA)

3128. Genome-wide DNA methylation analysis in blood and dermal fibroblasts from twin pairs discordant for systemic sclerosis

**Monday 09.11.2015 17:15**

Session: B-cell biology and targets in autoimmune disease: novel B cell roles in rheumatoid arthritis and systemic lupus erythematosus (West 2014)

Levels M (The Netherlands)

3155. Bob1 expression is elevated in rheumatoid synovium and its expression in B cells is required for development of collagen induced arthritis

---

**POSTERS**

**Monday 09.11.2015**

Nakamura S (Japan)

1243. Identification of the gene expression signatures predicting the responses to three biologics (infliximab, tocilizumab and abatacept)

Karouzakis E (Switzerland)

1265. Genetic and epigenetic mapping of very early RA synovial fibroblasts

---

Ania Olewicz-Gawlik

**MD, PhD** is an academic teacher and postdoctoral research fellow at the Department of Rheumatology and Clinical Immunology at Poznan University of Medical Sciences. Her professional interest focuses on systemic sclerosis, Sjögren’s syndrome and immunology.
BASIC RESEARCH II

Immunity, immunology

Francesco Carubbi

ORAL PRESENTATIONS

Monday 09.11.2015 14:30
Session: Cytokines, mediators, cell-cell adhesion, cell trafficking and angiogenesis II (South Esplanade 302)
Loupasakis K (USA)
2012. TNF confers pathogenic memory in synovial fibroblasts via chromatin remodeling, NF-Kb-dependent transcription and MAPK-mediated mRNA stabilization.

Monday 09.11.2015 15:00
Session: Cytokines, mediators, cell-cell adhesion, cell trafficking and angiogenesis II (South Esplanade 302)
Yao G (China)
2014. Deficiency of IL-27 exacerbate Sjögren's Syndrome through inhibiting differentiation of type 1 regulatory T cells

Tuesday 10.11.2015 16:30
Session: B cell biology and targets in autoimmune disease: novel B cell roles in rheumatoid arthritis and systemic lupus erythematosus (West 2014)
Buckner H (USA)
3152. The IL-21 signaling pathway is enhanced in RA B cells and has the potential to alter development and cytokite production in RA B Cells.

Tuesday 10.11.2015 17:00
Session: B cell biology and targets in autoimmune disease: novel B cell roles in rheumatoid arthritis and systemic lupus erythematosus (West 2014)
Corsiero E (United Kingdom)
3154. The importance of somatic hypermutation for the immunoreactivity towards neutrophil extracellular traps (NETs)-citrullinated autoantigens of RA synovial monoclonal antibodies

Tuesday 10.11.2015 17:45
Session: B cell biology and targets in autoimmune disease: novel B cell roles in rheumatoid arthritis and systemic lupus erythematosus (West 2014)
Wei C (USA)
3157. B cell profile as a biomarker of disease segmentation and flare prognosis in SLE

POSTERS

Monday 09.11.2015
Orange DE et al. (USA)
1933. Rheumatoid arthritis patient T cells recognize neutrophil extracellular traps

Tuesday 10.11.2015
Klose A. et al. (Germany)
3029. Increased plasticity of non-classic Th1 cells towards the Th17 phenotype
Barbara Ruaro
MD, works in the Academic Division of Clinical Rheumatology in Genoa, Italy. She is starting her PhD in Immunology in 2015.

ORAL PRESENTATIONS

Sunday 08.11.2015 15:45
Session: Rheumatoid arthritis - human etiology and pathogenesis I (North 130)
van Wesemael T (Netherlands)
966. In rheumatoid arthritis, smoking is not associated with anti-citrullinated protein antibodies per se, but with the concurrent presence of rheumatoid factor, anti-citrullinated protein antibodies and anti-carbamylated protein antibodies

Sunday 08.11.2015 17:30
Session: Rheumatoid arthritis - clinical aspects I - treatment advances and strategies (South Hall A)
Hazlewood GS (Canada)
1043. Enhancing comparative effectiveness research by combining observational and randomized trial data to personalize the choice between methotrexate and triple therapy for methotrexate-naive patients with early rheumatoid arthritis

Monday 09.11.2015 14:45
Session: Rheumatoid arthritis - clinical aspects II: infection, malignancy and other comorbidities in RA (South Esplanade 504)
Yun H (USA)
2049. Long term effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases

Tuesday, 10.11.2015 17:45
Session: Rheumatoid arthritis - clinical aspects V: goal = remission (West 2001)
Kuriya B (Canada)
3187. Predictors of disease relapse and recapture of remission following relapse in an Ontario rheumatoid arthritis population

POSTERS

Sunday 08.11.2015
Rannio T (Finland)
448. A majority of early rheumatoid arthritis (ERA) patients reach remission by 6 months in usual rheumatology care

Sunday 08.11.2015
Jonsson MK (Norway)
468. Clinical and ultrasonographic inflammation in DMARD-naive early rheumatoid arthritis (RA) – impact of the 2010 ACR/EULAR classification criteria versus the 1987 ACR classification criteria
Katrin Thorarinsdottir MD is a rheumatologist and a PhD student at the Sahlgrenska University Hospital, Gothenburg, Sweden. Her main research interest is the role of B cells in the pathogenesis of rheumatoid arthritis.

**ORAL PRESENTATIONS**

**Sunday 08.11.2015 17:15**

Session: Rheumatoid arthritis - clinical aspects I - treatment advances and strategies (South Hall A)
Ghiti Moghadam M (The Netherlands)
1042. Pragmatic multicenter open-label randomized controlled trial of stopping TNF-inhibitors in rheumatoid arthritis patients in remission or stable low disease activity in the Netherlands

**Monday 09.11.2015 17:00**

Session: Rheumatoid arthritis - small molecules, biologics and gene therapy IV: safety of targeted therapies (South Hall A)
Jani M (United Kingdom)
2140. Drug specific risk and associated factors for vasculitis-like events in patients exposed to tumour necrosis factor inhibitor therapy: results from the british society for rheumatology biologics register for rheumatoid arthritis

**Tuesday 10.11.2015 15:00**

Session: Rheumatoid arthritis - small molecules, biologics and gene therapy V: immunogenicity (West 2001)
Moots RJ (United Kingdom)
3112. Incidence of anti-drug antibodies in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab in a real-world setting

**Monday 09.11.2015 17:00**

Session: Rheumatoid arthritis - small molecules, biologics and gene therapy IV: safety of targeted therapies (South Hall A)
Jani M (United Kingdom)
2140. Drug specific risk and associated factors for vasculitis-like events in patients exposed to tumour necrosis factor inhibitor therapy: results from the british society for rheumatology biologics register for rheumatoid arthritis

**Tuesday 10.11.2015 16:45**

Session: Rheumatoid arthritis - small molecules, biologics and gene therapy VI: strategies (South Esplanade 307)
Sode J (Denmark)
3195. Circulating micro-RNA profiles in responders to adalimumab plus methotrexate versus methotrexate alone: a placebo-controlled clinical trial

**POSTERS**

**Monday 09.11.2015**

Fleischmann R (USA)
1642. A systematic review and network meta-analysis on the efficacy of tumor necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in methotrexate inadequate responders with rheumatoid arthritis

**Tuesday 10.11.2015**

Keystone EJ (Canada)
2783. What is the rate of primary and secondary failure of anti-TNF in RA patients? Data from a rheumatoid arthritis cohort

**Monday 09.11.2015**

Harrold L (USA)
1637. TNFi combination therapy, switching and
Jan Leipe
MD, board-certified rheumatologist, has completed specialist training in rheumatology and general internal medicine and is currently an attending physician at University of Munich, Germany. His major research interests include early rheumatoid arthritis and the role of T cells in the pathogenesis of autoimmune arthritis.

RA III
Other biologics and new drugs beyond biologics

Jan Leipe

ORAL PRESENTATIONS

Sunday 08.11.15 16:30
Session: Rheumatoid arthritis - small molecules, biologics and gene therapy II: small molecular targeted therapies (South Gateway Ballroom, 102) Fleischmann R (USA) 1045. Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with early rheumatoid arthritis who had received limited or no treatment with disease-modifying anti-rheumatic drugs (DMARDs): arthritis (RA) phase 3 trial results

Tuesday 10.11.15 14:45
Session: Rheumatoid arthritis - small molecules, biologics and gene therapy V: immunogenicity (West – 2001) Burmester G (Germany) 3111. Long-term safety and efficacy of mavrilumumab, a fully human granulocyte-macrophage colony-stimulating factor receptor-α (GM–CSFR-α) monoclonal antibody, in patients with rheumatoid arthritis who had received limited or no treatment with disease-modifying anti-rheumatic drugs (DMARDs): arthritis (RA) phase 3 trial results

POSTERS

Sunday 08.11.2015
Herold M (Austria) 499. Efficacy of tocilizumab monotherapy in patients with RA is not influenced by ACPA positivity

Monday, 09.11.2015
Hill RJ (USA) 1671. Discovery of PRN1008, a novel, reversible covalent BTK inhibitor in clinical development for rheumatoid arthritis

Monday, 09.11.2015
Monnet E (Switzerland) 1661. Translational data and phase 1 study results of a new monoclonal antibody targeting toll like receptor 4 (TLR4) developed for rheumatoid arthritis (RA) treatment with a potential for personalized medicine

Monday, 09.11.2015
Takeuchi T (Japan) 1672. One-year safety of sirukumab monotherapy: results from a randomized, double-blind, parallel-group, multicenter study in Japanese subjects with moderate to severe rheumatoid arthritis
PSORIATIC ARTHRITIS

Mislav Radić

ORAL PRESENTATIONS

Sunday 08.11.2015 15:30
Session: Spondylarthropathies and psoriatic arthritis - clinical aspects and treatment: treatment of AS (South Esplanade 307)
Mease PJ (USA)
977. A randomized, double-blind, active- and placebo-controlled phase 3 study of efficacy and safety of ixekizumab, adalimumab, and placebo therapy in patients naïve to biologic disease modifying anti-rheumatic drugs with active psoriatic arthritis

Sunday 08.11.2015 14:30
Session: Spondylarthropathies psoriatic arthritis - pathogenesis, etiology (West 2014)
Eder L (Canada)
979. HLA class I genes as susceptibility markers of psoriatic arthritis in patients with psoriasis – a meta-analysis

Tuesday 10.11.2015 15:00
Session: Spondylarthropathies and psoriatic arthritis - Clinical aspects and treatment: psoriatic arthritis – Co-morbidities
Mease PJ (USA)
3118. Clinical characteristics and disease outcomes in psoriatic arthritis patients by extent of body surface area affected by psoriasis: results from Corrona registry

POSTERS

Sunday 08.11.2015
Kavanaugh A (USA)
692. Association between improvement in enthesopathy and quality of life: results from a phase 3 trial in psoriatic arthritis patients

Monday 09.11.2015
Mease PJ (USA)
1694. All-cause mortality and malignancies in psoriasis patients with psoriatic arthritis in the psoriasis longitudinal assessment and registry study

Tuesday 10.11.2015
Valerio-Morales IA (Mexico)
2858. A phosphodiesterase 4 inhibitor for psoriatic arthritis: systematic review and meta-analysis
Victoria Navarro, MD, is working combining clinical practice and research at University Hospital La Paz in Madrid, Spain. She is also a PhD candidate at Leiden University Medical Center in Leiden, the Netherlands. Her main interests are focused in assessing inflammation and damage in axial spondyloarthritis and rheumatoid arthritis.
Christophe Richez

MD, PhD, is a Professor of Rheumatology at Bordeaux Hospital affiliated with University of Bordeaux. His main clinical interests are lupus and rheumatoid arthritis. His current research focuses on the involvement of T follicular helper T cells in different inflammatory diseases.

**ORAL PRESENTATIONS**

**Monday 09.11.2015 11:45**
Session: ACR plenary session II: discovery 2015 (South Hall A)
El Miedany YM (Egypt)

**Monday 09.11.2015 15:00**
Session: Systemic lupus erythematosus - human etiology and pathogenesis: modulators of disease (North 130)
Silverman GJ (USA)
2077 - Does dysbiosis within the intestinal microbiome contribute to SLE pathogenesis?

**Monday 09.11.2015 15:45**
Session: Systemic lupus erythematosus - human etiology and pathogenesis: modulators of disease (North 130)
Lood C (USA)
2073. Mitochondrial ROS is a novel regulator of sting-mediated type I IFN production by governing extrusion of oxidized mitochondrial DNA upon neutrophil extracellular trap formation

**POSTERS**

**Sunday 09.11.2015**
Kastborn A (Sweden)
786 - Anti-carbamylated protein antibodies identify systemic lupus erythematosus patients with erosive arthritis: analysis of a regional swedish register

Scalzi L (USA)
791 - Impact of Online Education and Social Media Intervention for Self-Management in Adolescents with SLE
OTHER CONNECTIVE TISSUE DISEASES
Including systemic sclerosis, myositis, vasculitis

John Pauling

BMedSci, BMBS, MRCP, PhD, is a consultant rheumatologist at the Royal National Hospital for Rheumatic Diseases, Bath, UK and Visiting Senior Lecturer at the University of Bath. His major research interest is assessing peripheral microvascular dysfunction in Raynaud’s phenomenon and systemic sclerosis.

ORAL PRESENTATIONS

Sunday 08.11.2015 16:30
Session: Systemic sclerosis, fibrosing syndromes, and Raynaud’s - Clinical aspects and therapeutics I (West 2001)
Clements PJ (USA)
1075. The scleroderma lung study II (SLS II) shows that both oral cyclophosphamide (CYC) and mycophenolate mofitil (MMF) are efficacious in treating progressive interstitial lung disease (ILD) in patients with systemic sclerosis (SSc)

Monday 09.11.2015 17:30
Session: Vasculitis II (West 2022)
Luqmani R (United Kingdom)
2160. The role of ultrasound compared to biopsy of temporal arteries in the diagnosis and treatment of giant cell arteritis: a diagnostic accuracy and cost effectiveness study

Monday 09.11.2015 11:30
Session: ACR plenary session II: Discovery 2015 (South Hall A)
Salmon JE (USA)
1996. Complement activation predicts adverse pregnancy outcome in patients with SLE and/or aPL antibodies

Tuesday 10.11.2015 12:15
Session: ACR plenary session III: Discovery 2015 (South Hall A)
Denton CP (United Kingdom)
3079. Efficacy and safety of riociguat in patients with pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD)

POSTERS

Sunday 08.11.2015
Leverenz D (USA)
300. Causes of creatine kinase levels greater than 1,000 IU/L in patients referred to rheumatology

Sunday 08.11.2015
Turk M (Canada)
835. A meta-analysis to determine if the prevalence of scleroderma renal crisis decreasing with time

Monday 09.11.2015
Owen C (Australia)
1984. Incidence and intensity of 18FDG uptake on whole body PET/CT in patients with polymyalgia rheumatica
Christian Dejaco

MD, PhD, MBA is a consultant and Associate Professor at the Medical University Graz. His main research interests are the value of ultrasound in psoriatic arthritis and vasculitis, clinical research on polymyalgia rheumatica and translational research on T lymphocyte senescence in rheumatology. He is the country liaison for EMEUNET in Austria.

IMAGING

Christian Dejaco

ORAL PRESENTATIONS

Sunday 8.11.2015 14:30 - 16:00
Session: Imaging of rheumatic diseases I: ultrasound
Aga AB (Norway)
926. Development of an ultrasound joint inflammation score for rheumatoid arthritis through a data-driven approach

Monday 9.11.2015 14:30 - 16:00
Session: Imaging of rheumatic diseases II: MRI, PET and CT
Wendling D (France)
2028. Contribution of 18f-fluoro-dexoxyglucose positron emission tomography for the diagnosis of polymyalgia rheumatica: a controlled study

Monday 9.11.2015 14:30 - 16:00
Session: Imaging of rheumatic diseases II: MRI, PET and CT
Bayat S (Germany)
2027. Development of a dual energy computed tomography scoring system for measurement of urate deposition in gout

POSTERS

Sunday 8.11.2015
Nam JL (United Kingdom)
152. Anti-CCP positive patients without clinical synovitis progress if ultrasound positive

Sunday 8.11.2015
Marschall A (Austria)
183. B-Mode and power doppler assessment as predictors for short and long-term clinical outcome in Cts patients with or without surgical treatment

Monday 9.11.2015 9:00 - 11:00
Sepriano A (Netherlands)
1327. Five-Year Follow-up of Radiographic Sacroiliitis: Progression As Well As Improvement?
Joanna Zalewska MD, PhD is a rheumatologist at the Jan Biziel Hospital in Bydgoszcz, Poland. Her main area of research focuses on RA, Sjogren Syndrome, Hashimoto disease, effectiveness of radiation synovectomy in rheumatic diseases, SLE and vasculitis.

**ORAL PRESENTATIONS**

**Monday 09.11.2015 17:15**

Session: Metabolic and crystal arthropathies I: therapeutics (West 2010)
Steinberg A (USA)
2111. A study to evaluate the efficacy and safety of arhalofenate for preventing flares and reducing serum uric acid in gout patients

**Monday 09.11.2015 17:30**

Session: Metabolic and crystal arthropathies I: therapeutics (West 2010)
Saag KJ (USA)
2112. Analysis of gout subjects receiving lesinurad and allopurinol combination therapy by baseline renal function

**Tuesday 10.11.2015 17:15**

Session: Metabolic and crystal arthropathies II: mechanisms and associations (North 130)
Merriman TR (New Zealand)
3167. Association of the apolipoprotein A1-C3-A4 gene cluster with the risk of gout: evidence for a causal role in gout

**POSTERS**

**Sunday 08.11.2015**

Perez-Ruiz F (Spain)
238. Relationship between ultrasonographic synovial inflammation and ultrasonographic urate deposition findings in patients with gout

Patel T (USA)
237. The prevalence of chondrocalcinosis of the symphysis pubis on CT scan and correlation with calcium pyrophosphate dihydrate crystal deposition disease

**Tuesday 10.11.2015**

Sankureddi P (USA)
2345. Canakinumab liquid formulation in acute gouty arthritis patients: long-term safety and efficacy results from a 36-week extension study

Choe JY (South Korea)
2346. Rebamipide suppresses monosodium urate crystal-induced interleukin-1b production through regulation of oxidative stress and caspase-1 in THP-1 cells
Marie Kostine MD, is a clinical fellow in Rheumatology at Bordeaux Hospital, France. She is currently working as a PhD candidate at the Leiden University Medical Center, Netherlands, on immune infiltrate in bone and soft-tissue tumours.

**OSTEOARTHRITIS AND OSTEOPOROSIS**

Marie Kostine

**ORAL PRESENTATIONS**

**Sunday 8.11.2015 11:30**

Session: ACR plenary session I: discovery 2015

Driban J (USA)

897. Intra-articular corticosteroids are safe and have no major effect on structural progression of synovitic knee OA: a 2-year randomized controlled trial of 3-monthly triamcinolone hexacetonide.

**Sunday 8.11.2015 11:45**

Session: ACR plenary session I: discovery 2015

Miller P (USA)

898. A randomized double-blind study of denosumab compared with zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonate.

**Sunday 8.11.2015 14:45**

Session: Osteoarthritis - clinical aspects: treatments and epidemiology

Pelletier JP (Canada)

950. In a two-year double-blind randomized controlled multicenter study, chondroitin sulfate was significantly superior to celecoxib at reducing cartilage loss with similar efficacy at reducing disease symptoms in knee osteoarthritis patients.

**Sunday 8.11.2015 15:00**

Session: Osteoarthritis – clinical aspects: treatments and epidemiology

Wang C (USA)

951. Comparative effectiveness of Tai Chi versus physical therapy in treating knee osteoarthritis: A randomized, single-blind trial.

**POSTERS**

**Sunday 8.11.2015**

Roux C (France)

333. Smoking and knee and hip osteoarthritis evolution. Results from the knee and hip osteoarthritis long-term assessment cohort.

**Sunday 8.11.2015**

Mathiessen A (Norway)

342. The effect of erosive status on systemic inflammatory biomarkers in hand osteoarthritis.

**Tuesday 10.11.2015**

Mahler E (Netherlands)

2412. Assessment and comparison of responsiveness of four patient reported outcome measures to assess physical function in patients with knee osteoarthritis: WOMAC-PF subscale responds best.
MD, s a research associate at the Department of Rheumatology of the University Hospital Ramon y Cajal, Madrid - Spain. His main research interest focuses on pediatric rheumatology, spondyloarthritis and biological therapies.

**ORAL PRESENTATIONS**

**Sunday 08.11.2015 15:15**

Session: Pediatric rheumatology - clinical and therapeutic aspects I: juvenile idiopathic arthritis (South Gateway Ballroom 102)

Klotsche J (Germany)

958. The time spent in inactive disease before MTX withdrawal is relevant with regard to the recurrence of active disease in juvenile idiopathic arthritis (JIA) patients.

**Monday 09.11.2015 15:15**

Session: Pediatric rheumatology - clinical and therapeutic aspects II: pediatric systemic lupus erythematosus (South Gateway Ballroom 102)

Nguyen J (Canada)


**Tuesday 10.11.2015 14:30**

Session: Pediatric rheumatology - clinical and therapeutic aspects III: Miscellaneous pediatric rheumatic diseases (South Gateway Ballroom 102)

Barron K (USA)

3092. Deficiency of adenosine deaminase type II - Expanding the clinical spectrum.

**Tuesday 10.11.2015 14:30**

Session: Pediatric rheumatology - clinical and therapeutic aspects IV: imaging and novel clinical interventions (North 132)

van Dijkhuizen P (Italy)

3176. New prospects for interpreting bony depressions in juvenile idiopathic arthritis: a novel MRI computer-assisted technique for detection of erosive progression.

**POSTERS**

**Sunday 08.11.2015**

Foeldvari I (Germany)

414. Performance of the adult systemic sclerosis classification in juvenile systemic sclerosis patients. Results from the juvenile dermatomyositis systemic sclerosis inception cohort

Consolaro A (Italy)


www.Juvenile-Scleroderma.com
EVENING WALKING TOUR

Sunday November 8th 2015

Fun walking tour of Chinatown, full of scandalous gold rush history and colorful tales of the city. The tour begins at 18.00 p.m from the Moscone Center and will take around 2 hours. Afterwards, on to a wonderful bar for drinks and bites. Cost: 18$ per person (drinks and food not included)
There are only limited spots available and they will be filled on a first come first serve basis!
Register by filling in the doodle at http://doodle.com/poll/gr4fsintxnhdw9yw

CABLECAR TOUR OF SAN FRANCISCO

Monday November 9th 2015

Join us for a ride in the famous cable cars. We’ll meet at the cable car turntable at Powell and Market street at 18.30 and take a ride to Fisherman's wharf. Everybody pays for their own tickets (6$).

JOIN EMEUNET ON SOCIAL MEDIA

We are proud to announce that in September of this year we celebrated one year since the launching of our EMEUNET Twitter. Follow @EMEUNET and become an active member of an exciting online community of rheumatologists and scientists; be the first to hear about job and other career opportunities and engage in educational and research activities.
During ACR Congress post photographic material from scientific and other sessions (within the legal regulations of the conference) including our hashtag (#EMEUNET) and handle (@EMEUNET).
Do not forget to LIKE also our Facebook page and follow the updates!
THE MENTOR MENTEE MEETINGS AT ACR 2015

Would you like to discuss your research and future career with a leader in the field in an informal way? Sign up for the mentor-mentees meetings at ACR in San Francisco 2015. The meetings will last approximately 60 minutes. Time and place have not yet been decided, and we will come back to you with this information. There won’t be any formal presentations as this meeting is only organized to give you a chance to have a chat with leaders in your area of research and discuss your career plans. The number of mentees will be 4-6 for each group. Here are the 4 professors that will guide as mentors in San Francisco:

Prof. Désirée van der Heijde
is professor of Rheumatology at the Leiden University Medical Center, Leiden, in The Netherlands as well as a senior researcher at Diakonhjemmet Hospital in Oslo, Norway. Her major research interest is outcomes assessment, especially its methodological aspects and application in clinical studies. Professor van der Heijde specializes in radiographic scoring methods in RA, PsA and SpA, as well as scoring of MRI in SpA. Professor van der Heijde was chairperson of ASAS from 1995 to 2012. She was also past chairperson of the EULAR Standing Committee for Clinical Affairs.

Prof. Lars Klareskog
is professor of Rheumatology and head of the Rheumatology Research Laboratory at the Center for Molecular Medicine at Karolinska Institute in Stockholm, Sweden. Prof. Klareskog's research is specifically aimed at the origin and treatment of autoimmune disorders. He described MHC class II-dependent cell activation as a pathogenic principle in rheumatoid arthritis in 1982. He initiated several national and international networks for rheumatology and epidemiology research, including a national network studying genes and environment in the etiology of arthritis (EIRA) and a national network for surveillance of arthritis patients treated with biologics (ARTIS) and a European collaborative group for surveillance and safety monitoring of biologics in arthritis. He was awarded with the Crafoord Prize in Polyarthritis in 2013.

Prof. Philip Conaghan
is the Chair of Musculoskeletal Medicine at the University of Leeds, and a Consultant Rheumatologist for the Leeds Teaching Hospitals NHS Trust. His major research area encompasses translational studies and clinical trials in understanding and treatment of rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Prof. Conaghan’s special interests are imaging biomarkers and outcome measurement. He was past chairperson of EULAR Standing Committee on Musculoskeletal Imaging. He also chaired the Assessment of Structural Change Working Group of the OARSI-FDA Initiative on osteoarthritis clinical trials. Prof. Conaghan is current Chair of the OMERACT Biomarkers and Imaging Workstream and Co-Chair of the OMERACT MRI Inflammatory Arthritis Task Force and Hip Osteoarthritis Task Force. Prof. Conaghan is co-editor of the Oxford Textbook of Rheumatology.

Assoc. Prof. Daniel Aletaha
is an associate professor and a consultant rheumatologist at the Medical University of Vienna. His major research interests are outcomes research, clinical trials, and translational research in rheumatoid arthritis and other inflammatory rheumatic diseases. Dr. Aletaha has been involved in several International Task Forces, including the development of the 2010 Classification Criteria for RA. He was a founding member and first Chairman of the “Emerging EULAR Network” (EMEUNET) in 2009. He also served as Chairman of the EULAR Standing Committee on Clinical Affairs from 2011-2013. Dr. Aletaha serves on the editorial board of Arthritis Research & Therapy, Annals of the Rheumatic Diseases and is an associate editor of Arthritis & Rheumatology.

If you want to attend any of these sessions, please send an email with your name, position, institute, who do you want to meet and why, copying us all to: yesimozguler@yahoo.com, kthorarins@gmail.com, luciasilvaf@yahoo.es, drsibelaydin@gmail.com, ida.k.haugen@gmail.com

Your EMEUNET Peer-Mentoring Subgroup
The fourth EULAR Epidemiology course took place in early July and was hosted by the German Rheumatism Research Centre, Epidemiology Unit and Charité University in Berlin. The course brought together 40 enthusiastic young researchers and 6 Faculty members from around Europe, organized by Pedro Machado and Laure Gossec (previous chairs of EMEUNET). The one and half day course addresses emerging and relevant concepts in epidemiology, with a balance of talks from renowned experts in the field and group workshops. This year’s course focused on clinical trial design, health economics, assessing safety in clinical trials and survival analyses, therefore having some epidemiological experience was essential to make the most of the course. Participants had the opportunity to explore certain topics in more detail via the workshops (critical appraisal of trials, analysing safety, calculating and interpreting QALYs, network metanalysis), which were both enjoyable and informative. In addition, short talks on organizing a small research unit and medical writing were presented by the organisers, following feedback from previous courses. This year, a ‘Meet the Professor’ session was introduced to allow delegates to meet members of the faculty (of their choice), which I personally found interesting and helpful. The evening consisted dinner games, group activities and opportunities to network with the group and organisers. Overall, I enjoyed the course and found it useful as it encompassed a variety of topics of emerging interest to researchers, consisted of engaging expert faculty members and was interactive with lots of opportunities to ask questions. The course was impeccably organized, with an excellent location of both the hotel and course venue. I would certainly recommend this course to other young rheumatology researchers with an interest in epidemiology and related concepts, who wish to improve and consolidate their existing knowledge of the themes covered.

Meghna Jani, EMEUNET Working Group Member, UK
<table>
<thead>
<tr>
<th>MONTH</th>
<th>EVENT</th>
<th>DATE</th>
<th>LOCATION</th>
<th>PROGRAMME</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>36th European Workshop for Rheumatology Research</strong></td>
<td>25-27 February</td>
<td>York, United Kingdom</td>
<td><a href="http://ewrr.org/index.html">http://ewrr.org/index.html</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="https://eiseverywhere.com/ehome/121743">https://eiseverywhere.com/ehome/121743</a></td>
</tr>
</tbody>
</table>
EDUCATIONAL EVENTS
MARCH-APRIL 2016

MARCH 2016

Intensive Course in Applied Epidemiology
- When: 7-11 March
- Where: Aberdeen, United Kingdom
- Website: [http://www.abdn.ac.uk/iahs/research/epidemiology/icae-aberdeen-course-158.php](http://www.abdn.ac.uk/iahs/research/epidemiology/icae-aberdeen-course-158.php)

BRS Training Course: Osteoporosis and Other Metabolic Bone Diseases
- When: 16-18 March
- Where: Oxford, United Kingdom
- Website: [http://boneresearchsociety.org/meeting/brsosteo2016/](http://boneresearchsociety.org/meeting/brsosteo2016/)

OARSI 2016 World Congress
- When: 31 March-4 April
- Where: Amsterdam, The Netherlands

APRIL 2016

1st EULAR Course on Immunology
- When: 1-2 April
- Where: Lisbon, Portugal

10th International Congress on Autoimmunity
- When: 6-10 April
- Where: Leipzig, Germany
- Website: [http://autoimmunity.kenes.com/](http://autoimmunity.kenes.com/)

XIX Pan-American League of Associations for Rheumatology Congress
- When: 10-14 April
- Where: Panama City, Panama

World Congress on osteoporosis, osteoarthritis and musculoskeletal diseases (WCO-IOF-ESCEO)
- When: 14-17 April
- Where: Malaga, Spain

Rheumatology 2016
- When: 26-28 April
- Where: Glasgow, United Kingdom
- Website: [https://elseverywhere.com/ehome/121743](https://elseverywhere.com/ehome/121743)
This open congress has the aim to discuss both practical and theoretical issues around running registers and longitudinal observational drug studies, generating output and understanding their results. The meeting will provide an opportunity for networking and development of international collaborative studies, which would be especially important for early-career investigators.

It will furthermore explore issues throughout the lifespan of studies, from first thoughts around establishing a register, practicalities such as funding, bio-banking and informatics, through methods of data collection, opportunities for harmonizing practice, analysis methodology, to the interpretation and dissemination of results.

Next EULAR RODS Meeting will take place in Prague 7-8 December 2015

Register now to save your place! Reduced registration fee until 11 November 2015

http://www.eular.org/epidemiology_registers_observational_drug_studies_meeting.cfm

For the 2015 preliminary programme visit:
THE EULAR ON-LINE COURSES

All EULAR courses, as electronic ways of continuous medical education in rheumatology, are managed by a scientific course committee responsible for the structure and content of the courses and for ensuring regular quality control and advancement. Teams of expert authors are regularly reviewing and updating the courses to keep up with the newest developments in the field. All courses are offered at EUR 100 per participant.

REGISTRATION IS OPEN UNTIL 1 NOVEMBER 2015

<table>
<thead>
<tr>
<th>Course</th>
<th>Duration</th>
<th>Link to course content</th>
</tr>
</thead>
<tbody>
<tr>
<td>10th EULAR On-line Course on Rheumatic Diseases</td>
<td>2 years</td>
<td><a href="http://www.eular.org/myUploadData/files/Online_full_module_planner.pdf">http://www.eular.org/myUploadData/files/Online_full_module_planner.pdf</a></td>
</tr>
<tr>
<td>7th EULAR On-line Course on Connective Tissue Diseases (CTD)</td>
<td>9 months</td>
<td><a href="http://www.eular.org/myUploadData/files/CTD%20wb%20overview%20modules_2012%20(2).pdf">http://www.eular.org/myUploadData/files/CTD%20wb%20overview%20modules_2012%20(2).pdf</a></td>
</tr>
<tr>
<td>5th EULAR On-line Course on Systemic Sclerosis (SSc)</td>
<td>9 months</td>
<td><a href="http://www.eular.org/myUploadData/files/SSc%20wb%20overview%20modules_2012.pdf">http://www.eular.org/myUploadData/files/SSc%20wb%20overview%20modules_2012.pdf</a></td>
</tr>
<tr>
<td>2nd EULAR / PReS On-line Course in Paediatric Rheumatology</td>
<td>9 months</td>
<td><a href="http://www.eular.org/edu_online_course_paediatric.cfm">http://www.eular.org/edu_online_course_paediatric.cfm</a></td>
</tr>
</tbody>
</table>

The EULAR On-line Courses on Rheumatic Diseases, CTDs, SSc and US are also available as APP

THE OPINION OF TWO PARTICIPANTS:

“Ultrasonography is essential for the training of Rheumatologists and represents a key aspect of patient’s evaluation. The EULAR On-line Introductory Ultrasound Course offers theoretical basic skills on musculoskeletal ultrasound in rheumatic diseases as well as in healthy subjects. The high quality of contents as well as the experience of the Faculty are the two main reasons to join this course. Moreover, the website is straightforward and very easy to use. Upon passing the final examination, EULAR releases a certificate. This course is very useful for Rheumatologists who would like to acquire a basic theoretical knowledge on musculoskeletal ultrasound.” (Francesco Carubbi)

“I attended the EULAR On-line Introductory Ultrasound Course. It is a well structured basic course on ultrasonography that is divided in different modules according to the different anatomical sites. Each module includes specific exercises and the final test. I found this course very interesting and it provided me with a complete overview of ultrasonography in rheumatology. I would recommend this course as to me it was overall more useful and formative compared to some different on-site courses I previously attended.” (Giulia Mirabelli)
New
1st EULAR Immunology Course

Date: 1-2 April 2016

Location: Nova Medical School, Lisbon, Portugal

Application: application form and additional information can be found on the EULAR website. Deadline: 9 December 2015

Costs: €150 (with 1 night accommodation) €200 (with 2 nights).
The fee covers: course, coffee, breaks, lunch (first day), dinner (first day), accommodation.

10 EULAR bursaries will be available (€500 each)

Apply before 9 December 2015

Join us and travel to the top in immunology!

Join us for the first EULAR immunology course designed for young rheumatologists and rheumatology researchers working in the field of immunology.

This course will offer a great opportunity to gain basic and in-depth knowledge about specific immunological hot topics.

Mentoring by experts in the field will teach you how to build a realistic research plan and how to apply for funding.

Network with faculty and other participants to build European collaborations which could be used to apply for EU-funding.

http://emeunet.eular.org
The course covers concepts and methods common to all chronic disease epidemiology. At the end of the course, delegates will have a thorough grounding in the principles of study design, the collection and analysis of data in epidemiological studies, and various methodological aspects of epidemiological study including bias, confounding, validity and reliability.

**Dates:** Monday 7th March – Friday 11th March 2016

**Venue:** University of Aberdeen, King's College, Old Aberdeen

**Cost:** £1300 including all course materials, accommodation and most meals. £1150 if booked by Friday 27th November 2016.

**Contact:** epidemiology@abdn.ac.uk

For further details: [www.abdn.ac.uk/epidemiology](http://www.abdn.ac.uk/epidemiology)
GREECE HAS A NEW COUNTRY LIAISON!

After 3 years and a wonderful job as Country Liaison for Greece, Antonis Fanouriakis hands over to Christina Tsalapaki!

Thank you, Antonis, for enthusiastically and constantly promoting of EMEUNET in Greece!

A warm welcome to Christina in the EMEUNET Country Liaisons team!

Christina has graduated from Athens Medical School and completed a MSc program in the University of Athens on “Cardiovascular and Intensive Care Medicine”. She gained international experience through the International Observership Program in the Rheumatology Department of Cleveland Clinic, Cleveland and Harvard Medical School, Boston. She recently completed the fellowship in Rheumatology and is a PhD candidate. Her scientific interests focus on systemic autoimmune diseases, mainly on vasculitis.

Email: c.tsalapaki@yahoo.com

INTRODUCING THE NEW COUNTRY LIAISON FOR SLOVENIA

After a years-long representation and development of the EMEUNET community in Slovenia, Mojca Frank Bertoncelj now hands over to Katja Perdan. We thank Mojca for an outstanding job as Country Liaison! We trust that Katja will do a wonderful job further promoting the EMEUNET/EULAR educational opportunities amongst Slovenian Rheumatologists. She will not be alone in this: researcher Polona Žigon will be her right hand, further advertising EMEUNET within the scientific community!

Katja is a rheumatology resident at Department of Rheumatology, University Medical Centre Ljubljana. She has defended her PhD thesis in 2013 and has experience as Assistant of Pharmacology and Experimental Toxicology, as well as Assistant of Internal Medicine. She also gained international experience through two visits at the Texas Heart Institute at St. Luke’s Episcopal Hospital (Houston, USA).

E-mail: katja.perdan@mf.uni-lj.si

GREAT PERSPECTIVES FOR EMEUNET IN ITALY!

EMEUNET is expanding in Italy! Sara Monti has been the Italian country liaison for almost a year and has done a fantastic job in setting up a young rheumatologist’s network in Italy. Her hard work and enthusiasm are paying off and have already inspired many young Italian rheumatologists to join our ranks.

Sara also made a great impression as she presented her activity during the Country Liaison meeting at EULAR 2015.

Go on with the great work, Sara!
EMEUNET @ DUTCH CONGRESS OF RHEUMATOLOGY

Marlies van der Goes, Country Liaison for The Netherlands promoted EMEUNET at the Dutch National Congress of Rheumatology (left picture). Dutch young Rheumatologists received flyers with information about EMEUNET to find out what EMEUNET is and learn more about EMEUNET activities (right picture).

EMEUNET @ IRISH CONGRESS OF RHEUMATOLOGY

Trudy McGarry, Country Liaison for Ireland promoted EMEUNET at the Irish Society of Rheumatology Congress (left picture) together with Mary Canavan, member of the Country Liaison Subgroup and Richard Conway, member of the Newsletter Subgroup. Dr. Michelle Trenkmann (right picture) and Dr. Lorna Gallagher concluded their abstract presentations discussing the role of EMEUNET and its benefits for young Rheumatologists.

An article about EMEUNET has also been published on The Medical Independent, a forthnightly newspaper aimed at Irish Doctors and can be found at the following link:

http://www.medicalindependent.ie/72806/benefits_of_european_rheumatology_network_promoted